Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection
NCT02772003Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2016
- Primary completion
- Mar 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of INO-8000 and ino-9012 in hepatitis C (HCV), sponsored by National Cancer Institute. Primary endpoints: Incidence of dose-limiting toxicity at 26 weeks and Mean change of interferon-gamma production by peripheral blood mononuclear cells at 26 weeks. Started Jun 2016; status: active, not recruiting.
02
Drugs
INO-8000ino-9012
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02772003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772003.